| Patent Number |
Title Of Patent |
Date Issued |
| RE33994 |
Pharmaceutical delivery system |
July 14, 1992 |
| A composition for use in an aqueous environment which .[.comprise.]. .Iadd.comprises .Iaddend.a formulation containing a water-soluble pharmaceutically beneficial agent, a water-insoluble, water-permeable film coating surrounding the formulation, and particulate, water-soluble, pore- |
| H692 |
Pest control |
October 3, 1989 |
| A method of treating an animal for the prevention or control of infestation by insects of the Order Diptera which comprises application to the animal of a compound of formula ##STR1## |
| D376847 |
Pharmaceutical tablet |
December 24, 1996 |
|
| D351795 |
Container cap |
October 25, 1994 |
|
| D346102 |
Cap opening aid |
April 19, 1994 |
|
| D334802 |
Tablet |
April 13, 1993 |
|
| D334535 |
Package |
April 6, 1993 |
|
| D269640 |
Medicinal tablet |
July 5, 1983 |
|
| D269128 |
Pharmaceutical tablet |
May 24, 1983 |
|
| 7098006 |
Chimeric antibody, pharmaceutical composition and process of its production |
August 29, 2006 |
| An altered antibody chain is produced in which the CDR's of the variable domain of the chain are derived from a first mammalian species. The framework-encoding regions of DNA encoding the variable domain of the first species are mutated so that the mutated framework-encoding regions |
| 5985318 |
Fusogenic liposomes that are free of active neuraminidase |
November 16, 1999 |
| Liposomes which have present on their surface a polypeptide capable of binding to a mucosal cell surface of a human or animal and which are substantially free of active neuraminidase are useful as vaccines. |
| 5654403 |
Immunoglobulins stabilized with a chelator of copper ions |
August 5, 1997 |
| A stabilized immunoglobulin composition comprises at least one immunoglobulin together with a stabilizing amount of a chelator of copper ions such as EDTA or citrate. Preferably the immunoglobulin is an antibody, for example, a recombinant CDR-grafted antibody. A process for enhancin |
| 5547976 |
Further indole derivatives with antiviral activity |
August 20, 1996 |
| The present invention relates to indolopyrolocarbazole derivatives, to their use in methods of treatment or prophylaxis of at least one viral infection or cardiovascular diseases; and pharmaceutical formulations containing such derivatives. |
| 5547664 |
Expression of recombinant proteins in attenuated bacteria |
August 20, 1996 |
| The invention concerns a vaccine comprising an attenuated Salmonella bacterium which contains a nirB promoter operably linked to a DNA sequence encoding a heterologous protein. The nirB promoter directs expression of the heterologous protein in a host it is wished to vaccinate. |
| 5545405 |
Method for treating a mammal suffering from cancer with a cho-glycosylated antibody |
August 13, 1996 |
| The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independentl |
| 5545404 |
Method for treating a mammal suffering from a T-cell medicated disorder with a CHO-Glycosylated |
August 13, 1996 |
| The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independentl |
| 5545403 |
Method for treating a mammal by administering a CHO-glycosylated antibody |
August 13, 1996 |
| The invention relates to a CHO cell-line capable of producing antibody, the cell-line having been co-transfected with a vector capable of expressing the light chain of the antibody and a vector capable of expressing the heavy chain of the antibody wherein the vectors contain independentl |
| 5534535 |
Therapeutic nucleosides |
July 9, 1996 |
| Antiviral nucleoside analogues contain a substituted benzimidazole base attached to a carbocyclic ring in place of the conventional sugar residue. Particularly preferred compounds include those in which the 2-, 5- and 6- positions of the benzimidazole base are substituted by halogen. The |
| 5512269 |
Method of treating retained pulmonary secretions |
April 30, 1996 |
| A method of facilitating the clearance of retained pulmonary secretions in a subject using lantibiotics is disclosed. The method comprises administering to the lungs of the subject an effective amount of a lantibiotic. The lantibiotic is preferably administered by topically applying |
| 5508310 |
Immunopotentiatory agents and physiologically acceptable salts thereof |
April 16, 1996 |
| This invention relates to the use of a class of compounds as immunopotentiaters, compositions containing such compounds and their manufacture, combinations of such compounds with anti-tumor or anti-infective drugs and the use of such combinations in the prophylaxis or treatment of su |
| 5495944 |
Bottle with tamper evident wrapping |
March 5, 1996 |
| Disclosed herein is a sealed tamper-evident container. The container comprises: a bottle having a side wall portion and an open mouth portion; a cap connected to the bottle mouth portion; a frangible label connected to the bottle side wall portion; a wrapper having an upper portion that |
| 5492897 |
Method for treating T-cell lymphoblastic leukemia with ara-G nucleoside derivatives |
February 20, 1996 |
| 6-Alkoxy derivatives of Ara-G, and pharmaceutically acceptable esters thereof, are described as being useful in tumor therapy. Novel pharmaceutically acceptable esters, their preparation and pharmaceutical formulations containing them are also disclosed. |
| 5466711 |
Medicaments |
November 14, 1995 |
| A method for treating or preventing a Pneumocystis carinii infection in a mammal by administering a certain naphthoquinone compound or physiologically acceptable salts thereof. |
| 5466711 |
Medicaments |
November 14, 1995 |
| A method for treating or preventing a Pneumocystis carinii infection in a mammal by administering a certain naphthoquinone compound or physiologically acceptable salts thereof. |
| 5466699 |
Indolyl compounds for treating migraine |
November 14, 1995 |
|
| 5466699 |
Indolyl compounds for treating migraine |
November 14, 1995 |
|
| 5461072 |
Use of aryl hydroxyurea compounds for the treatment of atherosclerosis |
October 24, 1995 |
| The present invention is concerned with the use of a compound of formula (I): Ar--Y--Q, wherein Ar is either (i) furyl, thienyl, thienyl 1,1-dioxide, pyrryl, pyridyl, benzofuryl, benzothienyl, benzothienyl 1,1-dioxide, indolyl, naphthyl, quinolyl, or tetrahydronaphthyl, any of which |
| 5459158 |
Pharmaceutical compositions of indazoles and methods of use thereof |
October 17, 1995 |
| Indazoles of Formula (I) ##STR1## in which R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each separately selected from hydrogen, halogeno, halogenoalkyl, formyl, carboxy, sulpho, cyano, nitro, COR and .sup.+ NRR'R" groups, wherein R, R' and R" are each separately alkyl, aralkyl or ar |
| 5453510 |
Neuromuscular blocking agents |
September 26, 1995 |
| 1R-cis,1'R-cis isomer of a 2',2'-(3,11-dioxo-4,10-dioxatridecylene)-bis(1,2,3,4-tetrahydro-6, 7-dimethoxy-2-methyl-1-veratrylisoquinolium) said, substantially free from other geometrical and optical isomers thereof. The 1R-cis,1'R-cis isomer has been found to have an advantageous com |
| 5447956 |
Treatment of leukemia with a imidazo carbamate |
September 5, 1995 |
| Use of Methyl N-[6-(3,4,5-trimethoxybenzyloxy)imidazo [1,2-6]pyridazin-2-yl]carbamate or pharmaceutically acceptable salt to treat lymphocytic leukemia is disclosed. |
| 5438120 |
Antigenic preparation and isolation of such preparations |
August 1, 1995 |
| Purified Bordetella pertussis antigen having a molecular weight between 67,000 and 69,000 and determined by 12% (W/W) polyacrylamide gel electrophoresis and a proline glutamic acid ratio of substantially 1:1 as determined by amino acid analysis. |
| 5432166 |
Use of 1-(.beta.-D-arabinofuranosyl) -5-propynyluracil for lowering serum cholesterol |
July 11, 1995 |
| The use of 1-(.beta.-D-arabinofuranosyl)-5-propynyluracil or a pharmaceutically acceptable salt or physiologically labile ester thereof for lowering serum cholesterol, particularly low density lipoprotein cholesterol levels in a human subject. |
| 5427798 |
Controlled sustained release tablets containing bupropion |
June 27, 1995 |
| A controlled sustained release tablet having at least one year shelf life and containing bupropion hydrochloride, hydroxypropyl methylcellulose and cysteine hydrochloride or glycine hydrochloride with the tablet having a surface area to volume ratio to effectively control bupropion h |
| 5424295 |
9-.beta.-D-arabinofuranasyl-2-amino-6-methaoxy-9H-purine |
June 13, 1995 |
| The compound 9-B-D-arabinofuranosyl-2-amino-6-methoxy-9H-purine along with its 5'-acetyl and 5'-(4-methoxy-4-oxobutyryl derivatives are disclosed as inhibitors of Varicella Zoster virus (VZV). |
| 5422373 |
Anti-atherosclerotic aryl compounds |
June 6, 1995 |
| Diaryl urea compounds having anti-atherosclerosis activity are disclosed. Preferred compounds include the compounds 1-[4-(1,2-dimethoxyethoxy)benzyl-3-(2,4-dimethoxyphenyl)-l-heptylumea and 1-heptyl-3-(2,4-dimethoxyphenyl)-l-[4-(2-methoxyethoxymethoxy)-benzyl]urea . |
| 5420156 |
Pharmacologically active compound and use |
May 30, 1995 |
| 1-Ethylphenoxathiin 10,10-dioxide (I) ##STR1## inhibits monoamine oxidase-A and is useful in the treatment of disorders such as depression. |
| 5416091 |
Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
May 16, 1995 |
| A method of treating multiple drug resistance of susceptible tumor cells in a subject in need of such treatment by using the compounds of formula (II): ##STR1## |
| 5409810 |
Nucelic acid derivatives |
April 25, 1995 |
| This invention relates to a methodology for assessing the sensitivity of an HIV-1 sample to zidovudine and to diagnostic assays for use in such assessment. |
| 5405872 |
Anti-hypertensive tetralins |
April 11, 1995 |
| This invention relates to tetralin derivatives useful in medicine for the treatment of hypertension, to the synthesis of the compounds, to the pharmaceutical formulations containing the compounds and the use of the compounds in medical practice. |
| 5405851 |
Pharmaceutical compounds |
April 11, 1995 |
| The present invention relates to novel benzoquinazoline thymidylate synthase inhibitors, to pharmaceutical formulations containing them and to their use in medicine. |
| 5405850 |
Antiviral compositions consisting of acyclovir and a 2-acetyl pyridine derivative |
April 11, 1995 |
| The present invention relates to a novel ribonucleotide reductase inhibitor and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemo-therapeutic treatment of virus infections, especially viruses |
| 5403934 |
Heterocyclic compounds |
April 4, 1995 |
| A compound of formula (I): ##STR1## wherein R.sup.1 represents a hydrogen or halogen atom, or a cyano group;R.sup.2 represents an optionally substituted carbocyclic group having 6 to 10 ring atoms and containing at least one aromatic ring; an optionally substituted heterocyclic group |
| 5399580 |
Therapeutic nucleosides-uses |
March 21, 1995 |
| Antiviral nucleoside analogues containing a substituted benzimidazole base attached to a carbocyclic ring in place of the conventional sugar residue, particularly those in which the 2-, 5- and 6-positions of the benzimidazole base are substituted by halogen, have activity against hep |
| 5399574 |
Indolyl tetrahydropyridines for treating migraine |
March 21, 1995 |
|
| 5395853 |
Anti-atherosclerotic diaryl compounds |
March 7, 1995 |
| The present invention is concerned with compounds of formula (I) ##STR1## wherein m is 0 or 1;W is hydrogen, a C.sub.1-16 straight, branched, or cyclic alkyl group, or a C.sub.2-16 straight, branched, or cyclic alkenyl or alkynyl group, orPh(CH.sub.2).sub.n -- where Ph is phenyl and n is |
| 5395610 |
Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
March 7, 1995 |
| Potentiating agents which enhance the efficacy of antineoplastic agents are disclosed. The potentiating agents disclosed are dibenz[b,e]oxepins such as doxepin. |
| 5393883 |
Antiviral combinations and compounds therefor |
February 28, 1995 |
| The present invention relates to novel ribonucleotide reductase inhibitors and new combinations comprising an antiviral compound, such as acyclovir, and a thiocarbonohydrazone ribonucleotide reductase inhibitor for the chemotherapeutic treatment of virus infections, especially viruses of |
| 5380759 |
Methyl N-[6-(3,4,5-trimethoxybenzloxy)imidazo[1,2-b]pyridazin-2-zyl]carbamate used to treat |
January 10, 1995 |
| Methyl N-[6-(3,4,5-trimethoxybenzloxy) imidazo [1,2-6]pyridazin-2-yl]carbamate is disclosed which is used to treat leukemia. |
| 5376644 |
Treatment of adenovical infections with 3'-fluoro-5-halo uracil compounds |
December 27, 1994 |
| 2',3'-Dideoxy-3'-fluoro pyrimidine nucleosides particularly 2', 3'-dideoxy-3'-fluorothymidine have been found to have particularly potent activity against adenovirus infections especially those caused by adenoviruses of scrotype 8. Such compounds are preferably presented in pharmaceu |
| 5371219 |
Imidazopyridazine derivatives |
December 6, 1994 |
| Compounds of general formula (I) ##STR1## wherein R.sup.1 represents an optionally substituted carbocyclic or heterocyclic aryl group, or an optionally substituted alkyl, alkenyl, cycloalkyl or cycloalkenyl group; R.sup.2 represents an optionally substituted alkyl, alkenyl, alkyn |
